Inhaled insulin getting close look by FDA

09/8/2005 | Reuters

The FDA has asked an advisory panel to consider if an inhaled insulin powder developed by Pfizer, Sanofi-Aventis and Nektar Therapuetics could have adverse effects on the lungs or blood sugar levels. The panel is scheduled to review Exubera today, and some analysts project the product, if approved, could generate sales of up to $2 billion a year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI